Back to Results
First PageMeta Content
Bevacizumab / Macular degeneration / Ophthalmology / Genentech / Ranibizumab / Choroidal neovascularization / Vascular endothelial growth factor / Presumed ocular histoplasmosis syndrome / Off-label use / Medicine / Health / Pharmacology


A Avastin versus Lucentis: Why It Matters lthough Lucentis is a remarkably safe and effective treatment for exudative macular degeneration, it could cost our health care system over $9 billion, which
Add to Reading List

Document Date: 2007-01-08 17:20:10


Open Document

File Size: 32,22 KB

Share Result on Facebook
UPDATE